An Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in High-Risk Outpatients With COVID-19 (MAOP3 Trial)
Latest Information Update: 12 Jun 2023
At a glance
- Drugs Upanovimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms MAOP3
- Sponsors Sinocelltech
- 24 Mar 2021 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.
- 24 Mar 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Jan 2022.
- 24 Mar 2021 Planned initiation date changed from 1 Mar 2021 to 28 Mar 2021.